Over the last few years, EGFR inhibitors have successfully joined the armamentarium of anti-
cancer drugs with an increasing number of indications such as colorectal cancer, head and
neck cancer, nonsmall cell lung cancer and breast cancer [1]. EGFR-targeted drugs consist
of monoclonal antibodies to EGFR (eg cetuximab, panitumumab), small-molecule tyrosine
kinase inhibitors specific for EGFR (eg erlotinib, gefitinib), dual kinase inhibitors inhibiting
EGFR and HER2 (lapatinib), pan-erbB inhibitors inhibiting EGFR and other erbB receptors …